Figure 9
Proposed mechanism of ADTM anti-platelet aggregation.
In part, ADTM binds with ERp57 and inhibits its redox activity, inhibits the activation of αIIbβ3 and the expression of P-selection and enhances the expression of HO-1 and phosphorylation of VASP. The crosstalk between ERp57 and αIIbβ3 is involved in the biological action of ADTM. In addition, ADTM reverses the decreased level of 6-Keto-PGF1α, a stable metabolite of PGI2 in the FeCl3-induced thrombosis model in vivo.
